Clinical Natural Language Processing (NLP)

We successfully completed a pilot project in mental health in collaboration with Obasi, and supported by Johnson & Johnson.

We are proud to share that we have been recognized as one of the World's Best Digital Health Companies by Newsweek and Statista!

LynxCare appoints Jeanne Kehren as new Chief Executive Officer. She succeeds Georges De Feu, LynxCare’s visionary founder, who stepped aside from his position as CEO.

As Heart Failure Awareness Week comes to a close, we wanted to take a moment to reflect on the insights shared throughout the week. We've delved into various aspects of heart failure management, from the promise of AI-NLP technology to bridging the gaps in heart failure research.

LynxCare is excited to announce the appointment of Laurent van Lerberghe, former Chief Strategy Officer at Sanofi, as Investor and Board Advisor. LynxCare is a scale-up company in Clinical Artificial Intelligence part of the CB Insights Global Digital Health 150, supported by renowned VC investors MTIP (CH), Elaia (FR), B2Ventures (CH-DE) and Heran partners (BE).

Through our comprehensive datasets, including an estimated 23.500 patients and 235 variables, you can gain further insights into the complexities of heart failure.

Leveraging cutting-edge AI and disease-specific Clinical NLP, LynxCare unlocks the richness of hospital data (incl. narrative text in medical records - unstructured data), building harmonized databases. Hospitals and life sciences can in turn extract clinical insights from fresh Real-World Data for research and improving patient care.

Unlocking New Possibilities for Pharma with our Lung Cancer datasets.

Our granular and quality-controlled real-world dataset allows in-depth analysis and research into the CLL patient journey.